Weight loss drugs have surged in popularity. But Gov. Ned Lamont wants CT’s Medicaid program to discontinue covering them for ...

In 2023, the United States marked a major milestone in the battle against a longstanding public health crisis: adult obesity rates dropped for the first time in a decade. Researchers pointed to GLP-1s ...

Eli Lilly on Thursday launched in India its diabetes and weight-loss drug, Mounjaro, which has already clocked in over $20 ...

Dawn Maroney became president of Alignment Health in January at a critical time for the health insurance industry.

Both semaglutide and tirzepatide would need big price cuts to be seen as a good buy for the US healthcare system.

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Drugmakers are urging the Trump administration and European Union officials to exclude medical goods from expanding tariff ...

Spring has nearly sprung and round two of the Inflation Reduction Act (IRA)’s negotiation period has begun. | All of the ...

A new study suggests blockbuster weight loss drugs Wegovy and Zepbound are not cost-effective at their current prices, despite the proven health benefits. The study, published in JAMA Health Forum and ...

Wegovy is a prescription medication designed for chronic weight management, offering hope to individuals struggling with ...

They’re expensive and aren’t a short-term fix, but Ozempic and Wegovy show great promise in regulating weight. | Opinion ...

All pharmaceutical manufacturers, including Novo Nordisk (NYSE:NVO) and Teva Pharmaceuticals, have agreed to participate in ...